Aldeyra Story

<div class='circular--portrait' style='background:#8B008B;color: #ffffff;font-size:4em;'>AT</div>
ALDX -- USA Stock  

USD 11.79  0.50  4.07%

As many millenniums are trying to avoid healthcare space, it makes sense to break down Aldeyra Therapeutics a little further and try to understand its current market patterns. We will try to explain if it is still possible for Aldeyra Therapeutics to generate above-average margins. Is Aldeyra Therapeutics valuation sustainable? Here I will cover a perspective on valuation of Aldeyra to give you a better outlook on taking a position in this stock.
Published over a week ago
View all stories for Aldeyra Therapeutics | View All Stories
Is Aldeyra Therapeutics (NASDAQ:ALDX) ready for a correction?
Aldeyra Therapeutics currently holds 15.01 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the firm is not taking enough advantage from borrowing. Our trade advice tool can cross-verify current analyst consensus on Aldeyra Therapeutics and to analyze the company potential to grow in the current economic cycle.
We determine the current worth of Aldeyra Therapeutics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Aldeyra Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Aldeyra Therapeutics's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Aldeyra Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aldeyra Therapeutics. We calculate exposure to Aldeyra Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Aldeyra Therapeutics's related companies.

Aldeyra Therapeutics Investment Alerts

Aldeyra investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Aldeyra Therapeutics performance across your portfolios.Please check all investment alerts for Aldeyra

Aldeyra Therapeutics Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Aldeyra value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aldeyra Therapeutics competition to find correlations between indicators driving the intrinsic value of Aldeyra.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Aldeyra Therapeutics, but it might be worth checking our own buy vs. sell analysis

Purchase by Perceptive Advisors Llc of 50000 shares of Aldeyra Therapeutics

Legal trades by Aldeyra Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Aldeyra insider trading alert for perchase of common stock by Perceptive Advisors Llc, the corporate stakeholder, on 11th of January 2021. This event was filed by Aldeyra Therapeutics Inc with SEC on 2021-01-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.


Net Loss for the year was (39.42 M) with profit before overhead, payroll, taxes, and interest of 0.

Aldeyra Therapeutics Average Equity is fairly stable at the moment. Also, Aldeyra Therapeutics Earnings before Tax is fairly stable at the moment.

Will Aldeyra Therapeutics growth be trustworthy after the rise?

Mean deviation is down to 3.14. It may suggest a possible volatility slide. Aldeyra Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Aldeyra Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Aldeyra Therapeutics future alpha.

Our Final Take On Aldeyra Therapeutics

While few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Aldeyra Therapeutics may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither acquire nor trade any shares of Aldeyra Therapeutics at this time. The Aldeyra Therapeutics risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aldeyra Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Aldeyra Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to